Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Syncell
AddedFeb 15, 2024
UpdatedJun 18, 2026
Syncell

Syncell

Series A

Syncell: Pioneering spatial biology with Microscoop™ technology for novel disease biomarker discovery.

HQ
Watertown, MA, US
Founded
2020
Overview
Compare
Fundraising
Employees
Website

Founded with a mission to revolutionize spatial biology, Syncell is a life science technology company that aims to advance the understanding of molecular mechanisms and disease biomarkers. The company's core product, Microscoop™, is an innovative technology that enables microscopy-guided nanoscale protein "scooping," facilitating unbiased subcellular spatial proteomics discovery. Syncell's offerings are designed to address a wide range of biological problems, aiding in the identification of novel disease biomarkers and druggable targets.

Syncell has garnered attention for its groundbreaking approach and has attracted notable investors and industry experts. The company's pioneering work in spatial biology has led to significant achievements, including the development of tools that enhance the precision and scope of proteomics research. Syncell's impact is evident in its contribution to the field of life sciences, providing researchers with powerful new methods to explore and understand complex biological systems.

Syncell - Similar Companies

Synlife logo

Synlife

synlifebio.com

Spear Bio logo

Spear Bio

spear.bio

Cellanome logo

Cellanome

cellanome.com

NanoMosaic logo

NanoMosaic

Deepcell logo

Deepcell

AtlasXomics logo

AtlasXomics

atlasxomics.com

Spatial Genomics logo

Spatial Genomics

Stellaromics logo

Stellaromics

stellaromics.com

Symic Biomedical logo

Symic Biomedical

Scribe Biosciences logo

Scribe Biosciences

Correlia Biosystems logo

Correlia Biosystems

bioSyntagma logo

bioSyntagma

biosyntagma.com

Panome Bio logo

Panome Bio

panomebio.com

Micronoma logo

Micronoma

micronoma.com

AI Proteins logo

AI Proteins

aiproteinstx.com

Syncell - Quick Facts

Who are Syncell's competitors?

Companies similar to Syncell include Synlife, Spear Bio, Cellanome and NanoMosaic.

When was Syncell founded?

Syncell was founded in 2020.

Where is Syncell's headquarters located?

Syncell's headquarters is located in Watertown, MA, US.

When was Syncell's last funding round?

Syncell's most recent funding round was for $8.1M (USD) in October 2023.

How much has Syncell raised to-date?

As of Oct 13, 2023, Syncell has raised a total of $15.1M (USD).

How many employees does Syncell have?

Syncell has 17 employees as of Feb 4, 2024.

Syncell - Classification

Ownership
  • Venture Capital
Technology
  • AI
  • Analytics
Geographic Exposure
  • Global
Model
  • Platform
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Biomarkers
  • Biotechnology
Tags
  • Biotech
  • Data
  • Research
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software